ArticlePharmacoEconomics - open2020

Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data.

Ash Bullement et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.